Postoperative nausea and vomiting (PONV) are unpleasant experiences. Howeve
r, there is no drug that is completely effective in preventing PONV. Wherea
s cost effectiveness analyses rely on specific health outcomes (e.g., years
of life saved), cost-benefit analyses assess the cost and benefit of medic
al therapy in terms of dollars. We hypothesized that patients were willing
to pay for a hypothetical new drug that would eliminate PONV. Eighty electi
ve day surgical patients using general anesthesia participated in the study
. After their recovery in the postanesthetic care unit, they were asked to
complete an interactive computer questionnaire on demographics, the value o
f avoiding PONV, and their willingness to pay for an antiemetic. Patients w
ere willing to pay US$56 (US$26 - US$97; median, 25%-75%) for an antiemetic
that would completely prevent PONV. Patients who developed nausea (n = 21;
26%) and vomiting (n = 9; 11%) were willing to pay US$73 (US$44-US$110) an
d $100 (US$61-US$200; median, 25%-75%), respectively (P < 0.05). Seventy-si
x percent of patients considered avoiding postoperative nausea and 78% of p
atients considered avoiding vomiting as important (<greater than or equal t
o>50 mm on a 0-100-mm visual analog scale). Nausea or vomiting in the posta
nesthetic care unit, greater patient income, previous history of PONV, more
importance placed on avoiding nausea and vomiting, increasing age, and bei
ng married are independent covariates that increase the willingness to pay
estimates. Patients associated a value with the avoidance of PONV and were
willing to pay between US$56 and US$100 for a completely effective antiemet
ic.